ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PBH vs NEO // EV/EBITDA & P/E VALUATION

Prestige Consumer Healthcare Inc. (NYSE) VS. NeoGenomics Inc. (NASDAQ) • 15-METRIC TALLY: PBH 7 — NEO 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PBH VS. NEO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PBH NEO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 54.70% 43.20% +11.50 PBH /gross-margins <GO>
Return on Invested Capital (ROIC) 13.80% -9.00% +22.80 PBH /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 7.0x — — TIE /valuation <GO>
Free Cash Flow Yield 10.67% -0.94% +11.61 PBH /fcf-yield <GO>
Operating Margin 28.40% -15.90% +44.30 PBH /operating-margins <GO>
Net Profit Margin 17.50% -14.80% +32.30 PBH /net-margins <GO>
Revenue Growth (YoY) -4.30% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.21 2.72 -0.51 NEO /balance-sheet <GO>
Piotroski F-Score Quality 6/9 5/9 +1.00 PBH /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 54.1 51.0 +3.17 PBH /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 11.3x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.31B $2.32B -$10.4M NEO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PBH REV NEO REV PBH GROSS % NEO GROSS % PBH FCF NEO FCF
FY 2025 $1.09B $727.3M 54.7% 43.2% $246.4M -$21.8M
FY 2024 $1.14B $660.6M 55.8% 43.9% $243.3M -$34.0M
FY 2023 $1.13B $0 — — $248.9M -$2.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PBH // BETA —
NEO // BETA —